Pfizer (PFE.US) Q3 profit exceeds expectations, non-COVID products grow by 7%, full-year performance guidance raised

Smart Finance APP has learned that Pfizer (PFE.US) released its financial report for the third quarter of fiscal year 2026 (ending September 27) before the market opened on November 3. Adjusted diluted earnings per share for the quarter were $0.87, flat year-on-year and significantly higher than the market consensus of $0.73; GAAP diluted earnings per share were $0.56, down 9% year-on-year. Total revenue for the quarter was $16.583 billion, basically unchanged from the previous year, including product revenue of $13.255 billion, alliance revenue of $2.851 billion (up 24%), and royalty revenue of $477 million.